Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes

Ana M. Catafau; Eduardo Tolosa; Patrice Laloux; Thierry Vander Borght; Michel Van Zandijcke; Frank De Geeter; Alain Destee; Marc Steinling; Lucette Lacomblez; Marie Odile Habert; Cornelius Weiller; Malte Clausen; Ulrich Bogdahn; Anton Haass; Carl Martin Kirsch; Angelo Antonini; Riccardo Benti; Sandro Sorbi; Alberto Pupi; Luís Cunha; Joao Pedroso de Lima J.P.; Frances Vallderiola; Francisco Lomeña; Jaime Kulisevsky; Ana M. Catafau; Robert Weeks; Muriel Buxton-Thomas; William R G Gibb; Paul M. Kemp; Susanne Asenbaum; Robert Dudczak

doi:10.1002/mds.20112

Impact of dopamine transporter SPECT using ¹²³I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes

Ana M. Catafau, Eduardo Tolosa, Patrice Laloux, Thierry Vander Borght, Michel Van Zandijcke, Frank De Geeter, Alain Destee, Marc Steinling, Lucette Lacomblez, Marie Odile Habert, Cornelius Weiller, Malte Clausen, Ulrich Bogdahn, Anton Haass, Carl Martin Kirsch, Angelo Antonini, Riccardo Benti, Sandro Sorbi, Alberto Pupi, Luís CunhaJoao Pedroso de Lima J.P., Frances Vallderiola, Francisco Lomeña, Jaime Kulisevsky, Ana M. Catafau, Robert Weeks, Muriel Buxton-Thomas, William R G Gibb, Paul M. Kemp, Susanne Asenbaum, Robert Dudczak

Research output: Contribution to journal › Article › peer-review

Abstract

Imaging with ¹²³I-Ioflupane single-photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS] from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of ^123I-Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients.

Original language	English
Pages (from-to)	1175-1182
Number of pages	8
Journal	Movement Disorders
Volume	19
Issue number	10
DOIs	https://doi.org/10.1002/mds.20112
Publication status	Published - Oct 2004

Keywords

I-Ioflupane
Dopamine transporter
Parkinsonism
SPECT

ASJC Scopus subject areas

Clinical Neurology
Neuroscience(all)

Access to Document

10.1002/mds.20112

Cite this

Catafau, A. M., Tolosa, E., Laloux, P., Vander Borght, T., Van Zandijcke, M., De Geeter, F., Destee, A., Steinling, M., Lacomblez, L., Habert, M. O., Weiller, C., Clausen, M., Bogdahn, U., Haass, A., Kirsch, C. M., Antonini, A., Benti, R., Sorbi, S., Pupi, A., ... Dudczak, R. (2004). Impact of dopamine transporter SPECT using ¹²³I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Movement Disorders, 19(10), 1175-1182. https://doi.org/10.1002/mds.20112

Impact of dopamine transporter SPECT using ¹²³I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. / Catafau, Ana M.; Tolosa, Eduardo; Laloux, Patrice; Vander Borght, Thierry; Van Zandijcke, Michel; De Geeter, Frank; Destee, Alain; Steinling, Marc; Lacomblez, Lucette; Habert, Marie Odile; Weiller, Cornelius; Clausen, Malte; Bogdahn, Ulrich; Haass, Anton; Kirsch, Carl Martin; Antonini, Angelo; Benti, Riccardo; Sorbi, Sandro; Pupi, Alberto; Cunha, Luís; de Lima J.P., Joao Pedroso; Vallderiola, Frances; Lomeña, Francisco; Kulisevsky, Jaime; Catafau, Ana M.; Weeks, Robert; Buxton-Thomas, Muriel; Gibb, William R G; Kemp, Paul M.; Asenbaum, Susanne; Dudczak, Robert.

In: Movement Disorders, Vol. 19, No. 10, 10.2004, p. 1175-1182.

Research output: Contribution to journal › Article › peer-review

Catafau, AM, Tolosa, E, Laloux, P, Vander Borght, T, Van Zandijcke, M, De Geeter, F, Destee, A, Steinling, M, Lacomblez, L, Habert, MO, Weiller, C, Clausen, M, Bogdahn, U, Haass, A, Kirsch, CM, Antonini, A, Benti, R, Sorbi, S, Pupi, A, Cunha, L, de Lima J.P., JP, Vallderiola, F, Lomeña, F, Kulisevsky, J, Catafau, AM, Weeks, R, Buxton-Thomas, M, Gibb, WRG, Kemp, PM, Asenbaum, S & Dudczak, R 2004, 'Impact of dopamine transporter SPECT using ¹²³I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes', Movement Disorders, vol. 19, no. 10, pp. 1175-1182. https://doi.org/10.1002/mds.20112

Catafau, Ana M. ; Tolosa, Eduardo ; Laloux, Patrice ; Vander Borght, Thierry ; Van Zandijcke, Michel ; De Geeter, Frank ; Destee, Alain ; Steinling, Marc ; Lacomblez, Lucette ; Habert, Marie Odile ; Weiller, Cornelius ; Clausen, Malte ; Bogdahn, Ulrich ; Haass, Anton ; Kirsch, Carl Martin ; Antonini, Angelo ; Benti, Riccardo ; Sorbi, Sandro ; Pupi, Alberto ; Cunha, Luís ; de Lima J.P., Joao Pedroso ; Vallderiola, Frances ; Lomeña, Francisco ; Kulisevsky, Jaime ; Catafau, Ana M. ; Weeks, Robert ; Buxton-Thomas, Muriel ; Gibb, William R G ; Kemp, Paul M. ; Asenbaum, Susanne ; Dudczak, Robert. / Impact of dopamine transporter SPECT using ¹²³I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. In: Movement Disorders. 2004 ; Vol. 19, No. 10. pp. 1175-1182.

@article{caa9593fb22342dfb1ecc05869562c5f,

title = "Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes",

abstract = "Imaging with 123I-Ioflupane single-photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS] from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I-Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients.",

keywords = "I-Ioflupane, Dopamine transporter, Parkinsonism, SPECT",

author = "Catafau, {Ana M.} and Eduardo Tolosa and Patrice Laloux and {Vander Borght}, Thierry and {Van Zandijcke}, Michel and {De Geeter}, Frank and Alain Destee and Marc Steinling and Lucette Lacomblez and Habert, {Marie Odile} and Cornelius Weiller and Malte Clausen and Ulrich Bogdahn and Anton Haass and Kirsch, {Carl Martin} and Angelo Antonini and Riccardo Benti and Sandro Sorbi and Alberto Pupi and Lu{\'i}s Cunha and {de Lima J.P.}, {Joao Pedroso} and Frances Vallderiola and Francisco Lome{\~n}a and Jaime Kulisevsky and Catafau, {Ana M.} and Robert Weeks and Muriel Buxton-Thomas and Gibb, {William R G} and Kemp, {Paul M.} and Susanne Asenbaum and Robert Dudczak",

year = "2004",

month = oct,

doi = "10.1002/mds.20112",

language = "English",

volume = "19",

pages = "1175--1182",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "10",

}

TY - JOUR

T1 - Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes

AU - Catafau, Ana M.

AU - Tolosa, Eduardo

AU - Laloux, Patrice

AU - Vander Borght, Thierry

AU - Van Zandijcke, Michel

AU - De Geeter, Frank

AU - Destee, Alain

AU - Steinling, Marc

AU - Lacomblez, Lucette

AU - Habert, Marie Odile

AU - Weiller, Cornelius

AU - Clausen, Malte

AU - Bogdahn, Ulrich

AU - Haass, Anton

AU - Kirsch, Carl Martin

AU - Antonini, Angelo

AU - Benti, Riccardo

AU - Sorbi, Sandro

AU - Pupi, Alberto

AU - Cunha, Luís

AU - de Lima J.P., Joao Pedroso

AU - Vallderiola, Frances

AU - Lomeña, Francisco

AU - Kulisevsky, Jaime

AU - Catafau, Ana M.

AU - Weeks, Robert

AU - Buxton-Thomas, Muriel

AU - Gibb, William R G

AU - Kemp, Paul M.

AU - Asenbaum, Susanne

AU - Dudczak, Robert

PY - 2004/10

Y1 - 2004/10

N2 - Imaging with 123I-Ioflupane single-photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS] from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I-Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients.

AB - Imaging with 123I-Ioflupane single-photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS] from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I-Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients.

KW - I-Ioflupane

KW - Dopamine transporter

KW - Parkinsonism

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=7244225004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7244225004&partnerID=8YFLogxK

U2 - 10.1002/mds.20112

DO - 10.1002/mds.20112

M3 - Article

C2 - 15390019

AN - SCOPUS:7244225004

VL - 19

SP - 1175

EP - 1182

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 10

ER -